Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Curtis, Jeffrey R.
Ndlovu, Matladi N.
de Longueville, Marc
Funding for this research was provided by:
UCB (Not applicable)